Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005;7 Suppl 5(Suppl 5):S37-43.

Adverse events associated with hormonal therapy for prostate cancer

Ravi J Kumar, Al Barqawi, E David Crawford

Adverse events associated with hormonal therapy for prostate cancer

Ravi J Kumar et al. Rev Urol. 2005.

Abstract

With expanding indications for androgen deprivation therapy for the treatment of prostate cancer, it is imperative that health care providers be cognizant of the possible adverse effects of therapy, as well as their prevention and treatment. Neurologic and psychiatric effects include depression and declines in cognitive function. Musculoskeletal effects of hormonal therapy include osteoporosis, decrease in muscle mass, and fatigue. Gynecomastia, weight gain, and erectile dysfunction are also seen, as are hematologic effects. Further research is needed to evaluate alternative forms of therapy, such as intermittent hormonal deprivation and antiandrogen monotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of bisphosphonate action.
See this image and copyright information in PMC

References

    1. American Cancer Society, authors. Cancer facts and figures 2004. [Accessed November 2004]. Available at: http://www.cancer.org/docroot/STT/stt_0.asp.
    1. Huggins C, Hodges CV. Studies on prostate cancer, effect of castration, of estrogen and of androgen injection of serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297. - PubMed
    1. Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22:2927–2941. - PubMed
    1. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90:427–432. - PubMed
    1. Bahrke MS, Yesalis CE , 3rd, Wright JE. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males. A review. Sports Med. 1990;10:303–337. - PubMed

Suggested Reading

    1. Jardin A, Wagner G, Khoury S, et al., editors. Recommendations of the 1st International Consultation on Erectile Dysfunction, cosponsored by the World Health Organization. Plymouth: Health Publications Ltd; 2000. pp. 709–726.

LinkOut - more resources